SCHEMBL1086322

SCHEMBL1086322

Cc1oc(C(C)(C)C)cc1C(=O)N1CCC2(CC1)CN(Cc1ccccc1C(F)(F)F)C(=O)O2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.51
ALDH1A1 P00352 8/20 0.45
MAPT P10636 3/20 0.45
GLA P06280 1/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
TDP1 Q9NUW8 2/20 0.38
ALOX15 P16050 2/20 0.38
EPHX2 P34913 2/20 0.38
TSHR P16473 2/20 0.38
KDM4E B2RXH2 4/20 0.38
LMNA P02545 3/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
GAA P10253 1/20 0.37
ATM Q13315 1/20 0.37
RAB9A P51151 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
HDAC11 Q96DB2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1086184 0.87 NPSR1 (0.47) NPSR1ALDH1A1MAPTGLAMEN1
SCHEMBL1087235 0.86 ALDH1A1 (0.44) NPSR1ALDH1A1MAPTGLAMEN1
SCHEMBL1086455 0.85 ALDH1A1 (0.45) NPSR1ALDH1A1MAPTMEN1KMT2A
SCHEMBL1086840 0.83 ALDH1A1 (0.44) NPSR1ALDH1A1MAPTGLAMEN1
SCHEMBL1086181 0.83 KDM4E (0.43) NPSR1ALDH1A1MAPTMEN1KMT2A
SCHEMBL1086371 0.82 ALDH1A1 (0.46) NPSR1ALDH1A1MAPTGLAMEN1
SCHEMBL1085995 0.82 EPHX2 (0.47) ALDH1A1MAPTMEN1KMT2ATDP1
SCHEMBL1086138 0.81 GRIN1 (0.39) NPSR1ALDH1A1MAPTMEN1KMT2A
SCHEMBL1086340 0.81 ALDH1A1 (0.44) NPSR1ALDH1A1MAPTGLAMEN1
SCHEMBL1086207 0.80 EPHX2 (0.45) ALDH1A1MAPTMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US disclosed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed
EP-1910381-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-04-16 EP disclosed
WO-2007000325-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC NPSR1 817/4885ALDH1A1 220/4885MAPT 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.